- Home
- NERV vs IMRN Comparison
NERV vs IMRN Comparison
Compare NERV & IMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NERV
- IMRN
- Stock Information
- Founded
- NERV 2007
- IMRN 1994
- Country
- NERV United States
- IMRN Australia
- Employees
- NERV N/A
- IMRN N/A
- Industry
- NERV Biotechnology: Pharmaceutical Preparations
- IMRN Biotechnology: Pharmaceutical Preparations
- Sector
- NERV Health Care
- IMRN Health Care
- Exchange
- NERV Nasdaq
- IMRN Nasdaq
- Market Cap
- NERV 14.6M
- IMRN 14.4M
- IPO Year
- NERV 2014
- IMRN N/A
- Fundamental
- Price
- NERV $3.78
- IMRN $1.74
- Analyst Decision
- NERV Hold
- IMRN
- Analyst Count
- NERV 1
- IMRN 0
- Target Price
- NERV $4.00
- IMRN N/A
- AVG Volume (30 Days)
- NERV 101.0K
- IMRN 389.2K
- Earning Date
- NERV 11-05-2025
- IMRN 08-29-2025
- Dividend Yield
- NERV N/A
- IMRN N/A
- EPS Growth
- NERV N/A
- IMRN N/A
- EPS
- NERV N/A
- IMRN N/A
- Revenue
- NERV N/A
- IMRN $4,777,422.00
- Revenue This Year
- NERV N/A
- IMRN N/A
- Revenue Next Year
- NERV N/A
- IMRN N/A
- P/E Ratio
- NERV N/A
- IMRN N/A
- Revenue Growth
- NERV N/A
- IMRN 48.63
- 52 Week Low
- NERV $1.15
- IMRN $1.42
- 52 Week High
- NERV $12.46
- IMRN $2.48
- Technical
- Relative Strength Index (RSI)
- NERV 49.13
- IMRN 49.05
- Support Level
- NERV $3.76
- IMRN $1.47
- Resistance Level
- NERV $4.42
- IMRN $1.77
- Average True Range (ATR)
- NERV 0.32
- IMRN 0.10
- MACD
- NERV -0.09
- IMRN 0.03
- Stochastic Oscillator
- NERV 25.93
- IMRN 91.53
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.
About IMRN Immuron Limited
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform focused on polyclonal antibodies that can address unmet medical needs. The company's commercial products are: Travelan (an orally administered passive product indicated to reduce the risk of travelers' diarrhea and minor gastrointestinal disorders), and Protectyn, which is marketed as an immune supplement. Additionally, it has two clinical products in development, IMM124-E and IMM529, for the treatment of multiple high-value enteric disease indications. The firm has two reportable segments: Hyper-immune products, which derive maximum revenue, and Research and development. Geographically, the company generates maximum revenue from Australia, followed by the USA and Canada.